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Editor: D. BarceloThe effects of pharmaceuticals and personal care products (PPCPs) on aquatic organisms represent a signiﬁcant cur-
rent concern. Herein, a targeted metabolomics approach using liquid chromatography-high resolution mass spec-
trometry (LC-HRMS) is presented to characterise concentration changes in 29 selected metabolites following
exposures of aquatic invertebrates, Gammarus pulex, to pharmaceuticals. Method performance revealed excellent
linearity (R2 N 0.99), precision (0.1–19%) and lower instrumental limits of detection (0.002–0.20 ng) for all metab-
olites studied. Three pharmaceuticalswere selected representing the low,middle andhigh range ofmeasured acute
measured toxicities (of a total of 26 compounds). Gammarids were exposed to both the no-observed-adverse-
effect-level (NOAEL) and the lowest-observed-adverse-effect-level (LOAEL) of triclosan (0.1 and 0.3 mg L−1),
nimesulide (0.5 and1.4mgL−1) andpropranolol (100 and153mg L−1) over 24h.Quantitativemetabolite proﬁling
was then performed. Signiﬁcant changes inmetabolite concentrations relative to controls are presented anddisplay
distinct clustered trends for each pharmaceutical. Approximately 37% (triclosan), 33% (nimesulide) and 46%
(propranolol) of metabolites showed statistically signiﬁcant time-related effects. Observed changes are also
discussed with respect to internal concentrations of the three pharmaceuticals measured using a method based
on pulverised liquid extraction, solid phase extraction and LC-MS/MS. Potentialmetabolic pathways thatmay be af-
fected by such exposures are also discussed. This represents theﬁrst study focussing onquantitative, targetedmeta-
bolomics of this lower trophic level benthic invertebrate that may elucidate biomarkers for future risk assessment.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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emerging class of environmental contaminants and their fate, occur-
rence and physicochemical behaviour in the aquatic environment
have been extensively studied and reviewed (Daughton and Ternes,
1999; Evgenidou et al., 2015; Monteiro and Boxall, 2010). The ecotoxi-
cological consequences of incomplete removal of pharmaceuticals
or their metabolites in wastewater or drinking water treatment
plants (WWTP/DWTP) are a matter of current environmental concern
which still requires further research (Gómez-Canela et al., 2013). Fur-
thermore, pharmaceuticals designed for hospital use are suspected to
have more adverse effects than other pharmaceuticals regarding their
effect on the aquatic environment (Gómez-Canela et al., 2014;
Franquet-Griell et al., 2015). As such, in the last decade, much research
has focused on understanding the occurrence and effects (Heberer,
2002) of these contaminants in exposed organisms. Recently, we devel-
oped a multi-residue analytical method and determined occurrence of
pharmaceuticals in tributaries of the River Thames and in Gammarus
pulex (G. pulex) at ng L−1 and ng g−1 concentrations respectively across
eight sites (Miller et al., 2015). G. pulex is a small, low trophic level spe-
cies of amphipod crustacean found in freshwaters across Europe and is
very common throughout the United Kingdom (UK). G. pulex has many
attributes for use in biomonitoring studies including its important role
in freshwater food chains where they serve as a food source for other
invertebrates, ﬁsh and birds (Maltby et al., 2002). This organism has
also been extensively used in contaminant monitoring including
toxicity assays for various pollutants such as metals, pharmaceuticals,
PAHs/PCBs and natural stressors which has shown the importance of
this species in environmental risk assessment (Bourgeault et al., 2013;
Coulaud et al., 2011; De Lange et al., 2006, 2009; Lebrun et al., 2012;
Maltby et al., 2002; Pellet et al., 2014; Schaller et al., 2011; Vellinger
et al., 2012).
Studies of the effects of pharmaceuticals on low trophic level inver-
tebrate organisms such as G. pulex using high resolution conﬁrmatory
chemical analysis techniques are lacking. In particular, metabolomics
may reduce this knowledge gap by directing effect-based studies that
reveal alternative markers or end-points to assess potential toxicity of
contaminants. Advances in mass spectrometry (MS) over the last de-
cade have enabled better characterization of the links between the me-
tabolome and phenotype (Dettmer et al., 2007; Villas-Bôas et al., 2005).
Targeted liquid chromatography coupled to mass spectrometry (LC-
MS) is the technique of choice for the reliable quantitation of known,
pre-selected metabolites. It is an approach that will increasingly be
used to apply knowledge discovered by non-targeted metabolomics;
i.e. the eventual targeted measurement of a metabolic biomarker signa-
ture that can predict exposure to a speciﬁc environmental stress (Viant,
2008; Viant and Sommer, 2013). Metabolomics studies have made use
of high resolution, conﬁrmatory analytical techniques such as nuclear
magnetic resonance (NMR) or hyphenated MS technologies to charac-
terise large numbers of compounds for metabolic proﬁling (targeted)
(Zhang et al., 2012). With the development of high resolution mass
spectrometry (HRMS), non-targeted screening of several thousand
compounds has become possible for studying larger portions of theme-
tabolome in contrast to NMR, which is often limited by low sensitivity
(Dunn et al., 2005; Zhang et al., 2012). Early investigations focused on
human, plant and microbial metabolomes (Frisvad and Filtenborg,
1983; Horning and Horning, 1971; Taylor et al., 2002; Tweeddale
et al., 1998). Other studies have identiﬁed changes in metabolomic
proﬁles in mussels resulting from hypoxic conditions; biomarkers asso-
ciated with withering syndrome in abalone sea snails; and responses to
ethinylestradiol (EE2) by rainbow trout (Hines et al., 2007; Samuelsson
et al., 2006; Viant et al., 2003). Approaches to characterise the metabo-
lome can involve non-targeted or targeted strategies where for quanti-
tative purposes, targeted analysis offers greater accuracy and precision
(Grifﬁths et al., 2010; Lei et al., 2011).The aimof thepresent studywas to develop a targetedmulti-residue
method for the determination of 29 metabolites pertaining to different
biochemical classes (amino acids, organic acids, nucleosides, nucleo-
tides, and sugars) using LC-HRMS. As a full scan method also suitable
for non-target analysis, the analytical performance of the method was
evaluated quantitatively in terms of comprehensive mass spectral
characterization, selectivity, sensitivity, intra- and inter-day precision,
range and linearity. Acute toxicity of 26 pharmaceuticals in G. pulex
was also assessed as an initial screen for compound selection for
metabolomics. Three pharmaceuticals showing low, median and
high measured LC50 values were then selected for exposures at no-
observed-adverse-effect-level (NOAEL) and lowest-observed-adverse-
effect-level (LOAEL) concentrations to evaluate alterations in the me-
tabolite proﬁle at 2, 6 and 24 h. This represents the ﬁrst environmental
metabolomics-based investigation of G. pulex by determining changes
in endogenous metabolites in response to pharmaceutical residue
exposure.
2. Materials and methods
2.1. Reagents, chemicals and consumables
All pharmaceuticals were purchased from Sigma-Aldrich
(Steinheim, Germany) and Fluka (Buchs, Switzerland) with a purity of
≥97%. HPLC grade acetone, dimethylsulfoxide (DMSO), ethanol (EtOH)
and methanol (MeOH) were purchased from Fischer Scientiﬁc (Lough-
borough, UK). Ultra-pure water was sourced from a Millipore Milli-Q
water puriﬁcation system with a speciﬁc resistance of 18.2 MΩ cm or
greater (Millipore, Bedford, MA, USA). Stock solutions (40 mg mL−1)
were prepared in ultrapure water, acetone, MeOH, EtOH or DMSO,
respectively. All stock solutions were stored in silanised amber vials
(40 mL) and at−20 °C in the dark for optimum stability. Organic sol-
vent concentration (acetone, MeOH, EtOH and DMSO) in aqueous solu-
tions used for toxicity testing was negligible. Metabolite standards
(organic acids, nucleosides, nucleotides, sugars and amino acids) were
supplied by Sigma Aldrich (Steinheim, Germany) and Fluka (Buchs,
Switzerland). In addition, the isotopically-labelled algal amino acidmix-
ture (98 atom% as 13C, 98 atom% as 15N) was provided from Sigma
Aldrich. The targeted metabolome studied was comprised of 15 amino
acids (AAs), 4 nucleosides, 2 nucleotides, 1 sugar, 3 organic acids and
4 compounds related to other families. Full details of the target metab-
olites and the labelled compounds are shown in Table 1. Finally, the 26
pharmaceutical compounds belonging to 12 different therapeutic
classes are listed in Table S1.
2.2. Sample collection and preparation
Adult G. pulex were collected several times between September
2014 and April 2015 from the River Cray, UK, a tributary of the River
Darent that feeds into the River Thames (51°23′10.5″N 0°06′34.8″E).
Adult specimens were collected via the kick sampling netting method.
Samples were transported back to the laboratory in Nalgene™ ﬂasks
containing a 500 mL grab sample of freshwater obtained from the
River Cray. This site has previously been demonstrated to have low
pharmaceutical contamination (bLOQ) (Miller et al., 2015). After collec-
tion, G. pulexwere stored in different artiﬁcial freshwater tanks and ac-
climatized for a minimum of 2–3 days at 15 ± 2 °C under a 12 h:12 h
light:dark cycle to allow depuration of any residual contamination.
The freshwater crustaceans were fed ad libitum with a minimum of
three horse-chestnut leaf discs (Ashauer et al., 2011). Artiﬁcial freshwa-
ter (AFW)was prepared following United States Environmental Protec-
tion Agency (USEPA) regulation (USEPA, 2002). Brieﬂy, 1.20 g MgSO4,
1.92 g NaHCO3 and 0.080 g KCl were added to 19 L of ultra-pure water
that was aerated overnight. In parallel, 1.20 g of CaSO4·2H2O was
added to 1 L of Milli-Q water and mixed with the previous salt solution
Table 1
Target analytes formetabolic proﬁling. Kegg number, molecular formula, molecular weight (Mw) andmass spectral characterization (ordered bymetabolic group) by LC-HRMS. Instrumental method performance. F: slope; R2: regression coefﬁcient;
IDL: instrumental detection limit; RSD: relative standard deviation; MDL: method detection limit.
Target compounds KEGG
number
Formula Mw Exact
mass
[M-H]− Linearity
(ng μL−1)
Calibration
type
F R2 IDL
(ng)
Intra-day precision
(5 ng μL−1)
Inter-day precision
(5 ng μL−1)
% Recovery ± RSD,
n= 3
MDL
(ng g−1)
L-2-Amino-n-butyric acid (AABA) C00334 C4H9NO2 103.06 103.0633 102.0560 0.05–15 External 1e6 0.993 0.06 9 2 107 ± 14 13.9
L-Alanine C00041 C3H7NO2 89.05 89.0477 88.0404 0.05–15 External 1e6 0.998 0.03 8 8 92 ± 9 0.99
L-Aspartic acid C00049 C4H7NO4 133.04 133.0375 132.0302 0.05–15 External 4e5 0.995 0.20 4 14 87 ± 11 22.7
L-Citrulline C00327 C6H13N3O3 175.09 175.0957 174.0884 0.1–15 External 1e6 0.999 0.15 2 6 87 ± 1 23.9
L-Isoleucine C00407 C6H13NO2 131.09 131.0946 130.0873 0.1–15 Internal 4.5 0.998 0.03 12 6 42 ± 8 0.28
L-Leucine C00123 C6H13NO2 131.09 131.0946 130.0873 0.1–15 Internal 1.6 0.994 0.02 13 9 99 ± 1 0.47
L-Methionine C00073 C5H11NO2S 149.05 149.0510 148.0437 0.05–15 Internal 21 0.997 0.02 5 6 67 ± 14 2.66
L-Ornithine hydrochloride C00077 C5H12N2O2 132.10 132.0899 131.0826 0.05–15 Internal 0.83 0.994 0.01 4 8 109 ± 6 3.51
L-Phenylalanine C00079 C9H11NO2 165.08 165.0790 164.0717 0.1–15 Internal 1.6 0.996 0.02 14 14 97 ± 4 0.42
L-(−)-Proline C00148 C5H9NO2 115.06 115.0633 114.0560 0.05–15 Internal 1.2 0.997 0.01 5 11 87 ± 8 1.13
L-Serine C00065 C3H7NO3 105.04 105.0426 104.0353 0.05–15 Internal 1.1 0.996 0.01 13 13 88 ± 14 9.50
L-Threonine C00188 C4H9NO3 119.05 119.0582 118.0509 0.1–15 Internal 2.0 0.999 0.2 13 7 103 ± 11 3.59
L-Tryptophan C00078 C11H12N2O2 204.09 204.0899 203.0826 0.1–15 External 7e6 0.998 0.02 8 6 102 ± 5 1.35
L-Tyrosine C00082 C9H11NO3 181.07 181.0739 180.0666 0.1–15 External 2.1 0.996 0.03 7 12 80 ± 8 0.35
L-Valine C00183 C5H11NO2 117.08 117.0790 116.0717 0.05–15 Internal 1.3 0.991 0.05 12 13 91 ± 6 0.80
Cytidine C00475 C9H13N3O5 243.08 243.0855 242.0777 0.05–15 External 3e6 0.999 0.01 8 1 110 ± 9 1.94
Inosine C00294 C10H12N4O5 268.09 268.0808 267.0734 0.01–15 Internal 1.01 0.995 0.002 1 14 108 ± 8 0.04
Thymidine C00214 C10H14N2O5 242.20 242.0903 241.0829 0.05–15 Internal 0.7 0.991 0.01 7 5 99 ± 7 0.50
Uridine C00299 C9H12N2O6 244.07 244.0695 243.0622 0.05–15 External 2e6 0.997 0.03 7 5 138 ± 2 0.33
ADP C00008 C10H15N5O10P2 427.03 427.0294 426.0221 3–15 External 7e5 0.993 0.15 9 11 25 ± 11 162
NADH C00004 C21H27N7O14P2 663.07 663.1091 662.1018 0.1–15 External 1e6 0.990 0.06 2 19 162 ± 10 7.80
Trehalose C01083 C12H22O11 342.12 342.1162 341.1089 0.05–15 External 2e6 0.996 0.01 10 0.2 81 ± 7 1.03
Creatine C00300 C4H9N3O2 131.07 131.0695 130.0622 0.1–15 External 3e5 0.991 0.11 3 0.5 107 ± 2 37.3
Phthalic acid C01606 C8H6O4 166.14 166.0266 165.0193 0.1–15 External 1e6 0.997 0.01 6 7 102 ± 2 13.6
Taurine C00245 C2H7NO3S 125.01 125.0147 124.0073 0.05–15 Internal 2.03 0.992 0.03 8 14 92 ± 20 0.23
1,7-Dimethylxanthine C13747 C7H8N4O2 180.20 180.0647 179.0574 0.05–15 Internal 1.19 0.997 0.01 10 13 72 ± 4 2.33
Hypoxanthine C00262 C5H4N4O 136.04 136.0385 135.0312 0.01–15 External 8e6 0.991 0.004 4 9 102 ± 7 0.47
Pyridoxine C00314 C8H11NO3 169.20 169.0739 168.0666 0.05–15 External 3e6 0.94 0.07 6 0.1 105 ± 10 21.6
(−)-Riboﬂavin C00255 C17H20N4O6 376.37 376.1383 375.1310 0.1–15 Internal 0.9 0.996 0.04 12 9 89 ± 7 6.50
13C,15N-Isoleucinea – C6H13NO2 138.12 138.1115 137.1041 – – – – – – – – –
13C,15N-Leucinea – C6H13NO2 138.12 138.1115 137.1041 – – – – – – – – –
13C,15N-Methioninea – C5H11NO2S 155.17 155.0646 154.0573 – – – – – – – – –
13C,15N-Phenylalaninea – C9H11NO2 175.12 175.1057 174.0984 – – – – – – – – –
13C,15N-Prolinea – C5H9NO2 121.09 121.0769 120.0695 – – – – – – – – –
13C,15N-Serinea – C3H7NO3 109.08 109.0495 108.0422 – – – – – – – – –
13C,15N-Threoninea – C4H9NO3 124.08 124.0685 123.0611 – – – – – – – – –
13C,15N-Valinea – C5H11NO2 123.10 123.0925 122.0852 – – – – – – – – –
a Internal standards used to quantify (Algal AA mixture).
779
C.G
óm
ez-Canela
etal./Science
ofthe
TotalEnvironm
ent562
(2016)
777–788
780 C. Gómez-Canela et al. / Science of the Total Environment 562 (2016) 777–788to make a total 20 L of AFW (USEPA, United States Environmental
Protection Agency USEPA, 2002).
2.3. Pharmaceutical exposures
To select speciﬁc pharmaceuticals, the concentrations for exposures
and subsequentmetabolite proﬁling, a series of acute toxicity tests to 26
pharmaceuticals were initially performed following the Organization
for Economic Co-operation and Development (OECD) 1488/94 guide-
line (European Communities Commission, 1996). Lethal median con-
centration effects and its 95% conﬁdence interval (CI), were estimated
by ﬁtting immobility concentration responses to the Hill regression
model (Eq. 1).
I Cið Þ ¼
1
1þ CiLC50
 −Hill ð1Þ
Where, I(Ci) is the proportion of immobile animals at concentration
Ci; Ci is the concentration of the respective compound (i); LC50 is the
median lethal concentration to the 50% of population and Hill is the
shape constant, which depends on the parameters adjusted in the re-
gression model. From these toxicity proﬁles the NOAEL and the LOAEL
were determined. Exposure experiments were performed in Pyrex®
beakers, each containing 200 mL of AFW at 15 °C and ten adult animals
(N5mgwet weight, ww). Live/dead animals were counted after 24 h by
gently prodding and observingmovement of appendages. The pharma-
ceutical concentrations tested were in the range of 0.01 to 250 mg L−1.
Control (AFW only) and solvent controls showed no measurable toxic-
ity. Concentrations where 100, 50 and 0% of the animals died were re-
peated in duplicate or triplicate.
From the initial toxicity tests on 26 pharmaceuticals, 3 were chosen
for metabolomics studies representing the high (triclosan), medium
(nimesulide) and low (propranolol) range of measured acute toxicity.
Each exposure consisted of G. pulex exposed at the NOAEL (C1) and a
second higher concentration at the LOAEL (C2) as follows: triclosan,
C1 = 0.1 mg L−1/C2 = 0.3 mg L−1; nimesulide, C1 = 0.5 mg L−1/
C2 = 1.4 mg L−1; and propranolol, C1 = 100 mg L−1/C2 =
153 mg L−1. Approximately 100 specimens were introduced in a tank
containing 1 L of AFW (control), 1 L of AFW spiked with C1 and 1 L of
AFW with C2. At three different times (2, 6 and 24 h), 4 replicates of
live G. pulex (a pool of 6–7 animals for each replicate) were collected,
frozen on dry ice and then stored at−80 °C before metabolite proﬁling
was performed. A preliminary extraction protocol with 1, 3, 6 and 10
animals showed that a pool of 6–7 G. pulex provided the best method
recoveries.
Quantiﬁcation of pharmaceutical concentrations in G. pulex at the
24 h exposure interval was performed. Separate exposures were set
up in triplicate in beakers containing 200 mL of exposure solution
(AFWspikedwith the respective C1 pharmaceutical dose) and 20organ-
isms. At 24 h, animals were immediately rinsed with ultra-pure water
and then frozen at−20 °C for 24h. Full analyticalmethod details are de-
scribed in Miller et al., 2015. Prior to extraction, frozen G. pulex samples
were lyophilised at −50 °C under vacuum for 48 h and milled in an
agate mortar to a ﬁne powder. For each analysis, 20 mg of a lyophilised
composite sample were transferred to 2 mL polypropylene tubes
(Eppendorf®, Hamburg, Germany), for solid-liquid extraction (SLE).
After the addition of 80 μL of stable isotope-labelled internal standards
at concentrations between 3.29 and 43.11 ng μL−1 (ﬁnal concentration
dependent on the AA concentration in the stock referencematerialmix-
ture), 800 μL of MeOH:HPLC water (90:10) mixture was added and the
samples were thoroughly mixed using a Vortex mixer. Then, samples
were shaken for 25 min on a vibration plate (IKA® KS 260 basic) and
centrifuged at 14,000 rpm for 25 min at 0 °C. Finally, the supernatant
was transferred to a chromatographic vial by using a 0.20 μM syringeﬁlter (Whatman, GE Healthcare Life Sciences, Buckinghamshire, UK).
All samples were stored at−80 °C until LC-HRMS analysis.
2.4. Internal pharmaceutical residue determination and metabolite
proﬁling
Internal concentrations of pharmaceuticals in G. pulex were deter-
mined using a previously describedmethod (Miller et al., 2015). Brieﬂy,
50 mg of lyophilised G. pulexwere extracted in 5 mL of acetonitrile and
pre-concentrated on Oasis HLB SPE cartridges (6 mL, 200 mg sorbent).
The extractwas eluted, dried-down and reconstituted in starting LCmo-
bile phase. The chromatographic separation followed a 75 min gradient
(including 12.5 min re-equilibration) using water and acetonitrile with
10 mM ammonium acetate salt. Separation was achieved using a
Waters Sunﬁre C18 reversed-phase column (2.1 × 150 mm, 2.5 μM
particle size) and detection was performed by a Waters Quattro triple
quadrupole mass analyser using positive and negative electrospray
ionization polarity switching (Waters Corporation, Milford, MA, USA).
Organic acids, nucleosides, nucleotides, sugars and AAs were measured
using LC–HRMS. An Exactive™mass spectrometer equipped with heat-
ed electrospray ionization (H-ESI) source was used (Thermo Fisher Sci-
entiﬁc, Bremen, Germany). The system was equipped with a HTC PAL
autosampler and a SurveyorMS Plus pump. A TSKGel-Amide 80 column
(2 × 250 mm, 5 μm) for analyte separation was purchased from Sigma
Aldrich. Mobile phases were binary mixtures of acetonitrile (A) and
5 mM ammonium acetate (pH 5) in HPLC-grade water (B). Gradient
elution started at 75% A and 25% B, which was increased linearly to
30% B in 8 min, increased linearly to 60% B to 12 min and then held
for a further 5 min. Initial conditions were returned in 3 min and the
system was stabilized after a total equilibration time of 10 min (total
run time = 30 min). The ﬂow rate was set at 150 μL min−1 and the
injection volume was 5 μL. Metabolites were analysed under positive/
negative ESI mode, but better resolution was obtained in negative ioni-
zation mode and so this was used for all experiments. Full scan acquisi-
tion over amass range of 80–800 Dawas performed at 70,000 full width
at half maximum (FWHM) and spray voltage at 3.00 kV, capillary volt-
age at 30 V, skimmer voltage at 28 V and tube lens voltage at 130 V
were used. A sheath gas ﬂow rate of 45 arbitrary units (au), an auxiliary
gas ﬂow rate of 10 au and a capillary temperature at 300 °C were
selected.
2.5. Method performance and quantiﬁcation
Methodperformance for internal pharmaceutical residue concentra-
tions in G. pulex are described elsewhere (Miller et al., 2015). Here,
pharmaceutical residue quantiﬁcation in exposed G. pulex was per-
formed by a 3-point matrix-matched calibration curve. For nimesulide,
spiking concentrations were 2.5, 5 and 10 μg g−1; for triclosan, these
were 1, 2.5 and 5 μg g−1; and for propranolol these were 1, 2.5 and
5 mg g−1. The calibration range for endogenous metabolites was from
0.01 to 15 ng μL−1, using 9 calibration points. The algal amino acid
mixture-13C,15N (see Table 1) was used as internal standard (IS) for
extraction and analytical control. L-ornithine hydrochloride, inosine,
thymidine, taurine, 1.7-dimethylxanthine and (−)-riboﬂavin were
quantiﬁed using either 13C,15N-proline or 13C,15N-tyrosine as the inter-
nal standard. The remaining 15 compounds were quantiﬁed using
external calibration and the target compound itself was used as external
standard. The instrumental detection limit (IDL) was initially calculated
as that concentration giving a signal intensity of 1 × 103, and afterwards
measured experimentally by injecting a standard concentration that
gave this signal intensity. Themethod detection limit (MDL) was calcu-
lated following the same procedure, using spiked lyophilised G. pulex
samples at a concentration of 1 μg g−1. Intra-assay variation was
assessed using ﬁve consecutive injections of 5 ng μL−1 standard solu-
tion, and inter-assay variation was determined by measuring the same
standard solution on four different days. Solvent blanks did not contain
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HRMS runs. Recovery studies were performed in triplicate, using
lyophilised G. pulex samples spiked at 1 μg g−1 with the metabolites
mixture and the algal amino acid mixture-13C, 15N. Five replicates of
a pool with 6–7 G. pulex were analysed ﬁrst and the traces of target
compounds were subtracted.
2.6. Statistical analysis
Two-way ANOVA considering signiﬁcant p values ≤ 0.05was used as
a ﬁrst step to select metabolites with signiﬁcant changes and to further
explore their concentration and time trends. Thus, p values were de-
rived and examined to determine any differences between exposed
and control specimens, and to evaluate the effect of the exposure
time. All data satisﬁed the assumptions of normality and homoscedas-
ticity. In addition, all calculations were performed in MATLAB software
version R2013b.
3. Results and discussion
3.1. Analytical method performance
Good correlation coefﬁcients (R2 ≥ 0.99) were obtained for 29 me-
tabolites (Table 1). Responses for ﬁfteen metabolites were linear from
0.05 to 15 ng μL−1; and for 11 other metabolites, linearity ranged
from0.1 to 15ng μL−1. Signals for inosine andhypoxanthinewere linear
over the range of 0.01 to 15 ng μL−1; and ADP in the range 3 to
15 ng μL−1. Therefore, given that this represents a lower concentration
range of 10 to 1500 ng g−1, these were considered ﬁt for purpose for
this study. IDL ranged from 0.002 to 0.20 ng, and intra and inter-day
precision ranges were from 1 to 14% and from 0.1 to 19%, respectively
at the 5 ng μL−1 concentration level. Twenty seven compounds showed
recoveries within the range of 42 ± 8% to 138 ± 2% (Table 1). Overall,
recoveries were acceptable and showed excellent precision. However,
the two nucleotides ADP and NADH displayed poorer recoveries of
25 ± 11% and 162 ± 10%, respectively. Finally, the MDL ranged from
0.04 (inosine) to 37.3 ng g−1 (creatine), with the exception of ADP,
for which sensitivity was low aswould be expected due to the lower re-
covery observed (MDL: 162 ng g−1). The extracted ion chromatograms
of a target metabolite mixed solution at 5 ng μL−1 using the TSK Gel-
Amide 80HILIC column is shown in Fig. 1. In summary, themethod per-
formance of this analytical method indicated that reliable quantitative
measurements could be made for most metabolites and with minimal
variance contribution from the matrix. Moreover, as this method incor-
porated HRMS in full-scan mode, post hoc untargeted data analysis of
the metabolome remains possible if required.
3.2. Acute toxicity, 24-h pharmaceutical exposures and observed changes in
target metabolite concentrations
Acute toxicity tests revealed LC50 at themg L−1 level for most of the
26 tested pharmaceuticals. Similar values have been obtained in other
freshwater crustaceans (see Table S3). Kim et al. (2009) studied
the acute toxicity of pharmaceuticals and personal care products in
the freshwater crustacean, Thamnocephalus platyurus (T. platyurus).
They reported a similar LC50 value to the present study for triclosan
(0.57 mg L−1), but not for propranolol which lay at 10.31 mg L−1
(Kim et al., 2009). These values provide a means of ranking the toxic
risk, but such values are not environmentally relevant as pharmaceuti-
cals are generally found at concentrations approximately one to two or-
ders of magnitude less (Miller et al., 2015). Therefore, it is unlikely that
the majority of these compounds will display any signiﬁcant acute tox-
icity. Nonetheless, as a starting point and based on these data, exposures
were performed at NOAEL and LOAEL concentrations for triclosan,
nimesulide and propranolol to represent compounds at the high, medi-
an and low range of measured LC50 (Figs. S1–S3).3.2.1. Triclosan
Triclosan, the most toxic of the selected pharmaceuticals (LC50
0.57mg L−1) measured here, caused changes in themetabolite concen-
trations inG. pulex at 0.1mg L−1 (C1) and 0.3mg L−1 (C2), andwas dose
responsive. Exposure to triclosan produced signiﬁcant changes (Two-
way ANOVA, p b 0.05) in 19 metabolites: 13 amino acids (L-alanine,
cytidine, L-citrulline, L-isoleucine, L-leucine, L-methionine, L-phenylala-
nine, L-proline, taurine, L-threonine, L-tryptophan, L-tyrosine and
L-valine), inosine and uridine (nucleosides) and others like trehalose,
hypoxanthine, riboﬂavin and thymidine (Table 2 and Figure S4). How-
ever, only the concentration of 37% of metabolites changed signiﬁcantly
(up or down) across the exposure time. L-isoleucine, L-phenylalanine, L-
(−)-proline, taurine, L-threonine, L-tyrosine, L-valine, inosine and thy-
midine concentrations varied signiﬁcantly (p b 0.05) with exposure du-
ration (Table 2). A 2-way ANOVA was used to evaluate the interaction
between dose and time factors. Cytidine, L-methionine, L-phenylalanine
and L-(−)-proline were the only metabolites that had signiﬁcant inter-
actions (Table 2). As shown in Figure S4, all metabolites except L-citrul-
line changed in their mean concentrations at C1 relative to the controls.
Somemetabolites increasedmore than two to three-fold in comparison
to controls such as L-tryptophan, hypoxanthine, L-alanine, L-isoleucine,
L-threonine, L-valine and L-thymidine. In other cases, measured concen-
trations between the exposed and control samples decreased over time
(ADP and L-proline). Similar trends occurred at C2 where the 75% of the
metabolites increased in their concentration, with the remaining me-
tabolites showing no signiﬁcant changes (also see Table S1). Table S2
shows the metabolite concentrations determined from all conditions
studied. To more conveniently highlight trends, Fig. 2 represents the
fold change values at each exposure concentration with respect to con-
trols and plotted in a heat map and hierarchical analysis revealed two
distinct clusters (A & B). In general, and for each metabolite in Cluster
A of Fig. 2, the fold changes in gammarid metabolites exposed at C1 de-
creased across the 24-h period. On the contrary, Cluster B generally
showed the opposite trend where concentrations of metabolites mostly
increased. In the case of samples exposed at C2, eight metabolites of
Cluster A (L-aspartic acid, L-leucine, L-valine, L-methionine, inosine, tau-
rine, L-tyrosine and thymidine) had a fold increase and the remainder
showed a slight decrease in concentration. The metabolites of Cluster
B also showed fold decreases along the 24-h period and the opposite
effect to those exposed at C1.3.2.2. Nimesulide
Exposure to nimesulide produced signiﬁcant changes (Two-way
ANOVA, P b 0.05) for 83% of the metabolites analysed, including most
amino acids (except L-alanine), such as inosine, uridine and other me-
tabolites including hypoxanthine, riboﬂavin and thymidine (Table 2
and Fig. S5). L-2-amino-n-butyric (AABA), L-alanine, L-aspartic acid,
cytidine, L-citrulline, L-leucine, L-(−)-proline, L-serine, trehalose and
thymidine showed a time-related effect (Table 2), affecting 42% of the
metabolites studied. On the other hand, considering the interaction
between time and dose factor, signiﬁcant differences (p b 0.05) in all
metabolites except for L-tyrosine and NADH were detected (Table 2).
Nimesulide exposures induced changes in the metabolome of G. pulex
in comparison to controls (Fig. S5). A heat map of nimesulide was pre-
pared as before and hierarchical analysis again revealed two clusters
(Fig. 3). In this case, at C1, all the metabolites except trehalose had fold
increases along the 24-h period (Cluster A, Fig. 3). Speciﬁcally, L-alanine,
(−)-riboﬂavin, cytidine, hypoxanthine, L-tryptophan, inosine, taurine,
L-tyrosine and NADH suffered the more important changes (garnet
colour). On the other hand, trehalose (Cluster B, Fig. 3) showed the
opposite trend and, at 24-h exposure time, the fold change had de-
creased (blue). In the samples exposed at C2, the metabolites in Cluster
A began with positive fold changes (red/orange) at 2-h exposure time
and decreased (blue) at 24-h exposure time, with the exception of
NADH, ADP and trehalose (Cluster B, Fig. 3).
Fig. 1. LC–HRMS extracted ion chromatogram of 29 target compounds from a full scan LC-Orbitrap-MS spectrum using a 5 ppm extraction window.
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Fig. 1 (continued).
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Table 2
Two-way ANOVA indicating p values for changes in metabolite concentrations based on time and dose factor. The signiﬁcant changes are in bold where p b 0.05.
p-Value
Triclosan Nimesulide Propanolol
Metabolite Dose
factora
Time
factorb
Interaction
dose × time
Dose
factora
Time
factorb
Interaction
Dose × Time
Dose
factora
Time
factorb
Interaction
dose × time
AABA 0.49 0.23 0.91 – 3e−4 0.003 – 0.24 0.32
L-Alanine – 0.19 0.15 0.53 – 6e−4 – 0.001 0.03
L-Aspartic acid 0.17 0.37 0.25 2e−4 0.005 0.004 0.28 0.04 0.44
Cytidine 0.001 0.08 0.02 – 0.02 – 5e−6 1e−5 1e−6
L-Citrulline 0.01 0.81 0.95 4e−6 2e−5 8e−6 0.53 0.29 0.07
L-Isoleucine – 9e−4 0.12 – 0.29 – 0.06 3e−4 0.003
L-Leucine 0.01 0.47 0.73 – 0.003 – 0.25 – –
L-Methionine – 0.18 0.003 – 0.15 1e−4 0.003 0.005 0.007
L-Ornithine hydrochloride Not detected in Gammarus pulex organism
L-Phenylalanine – 0.001 0.001 – 0.53 0.0001 0.69 – 0.001
L-(−)-Proline – 0.001 0.01 4e−7 6e−13 8e−9 – – 2e−4
L-Serine 0.21 0.05 0.23 0.04 0.02 0.03 – 0.73 0.01
Taurine – 0.002 0.10 – 0.58 0.002 0.03 0.05 0.75
L-Threonine – 0.03 0.07 – 0.07 0.001 0.34 – 0.001
L-Tryptophan – 0.28 0.53 – 0.08 – 0.0012 – –
L-Tyrosine – 0.01 0.40 0.003 0.97 0.12 0.70 0.01 0.27
L-Valine – 0.01 0.05 – 0.42 – 5e−4 2e−4 –
Inosine – 0.01 0.11 – 0.17 0.03 0.12 0.002 0.27
Uridine 8e−4 0.45 0.26 – 0.98 – 0.002 6e−4 0.009
ADP 0.21 0.25 0.74 0.04 0.14 0.01 0.02 0.87 0.64
NADH 0.05 0.41 0.31 0.49 0.72 0.12 0.52 0.58 0.83
Trehalose 0.03 0.11 0.08 0.07 – – 0.21 – –
Creatine Not detected in Gammarus pulex organism
1,7-dimethylxanthine Not detected in Gammarus pulex organism
Hypoxanthine – 0.08 0.07 – 0.14 – 1e−6 4e−5 8e−7
Phtalic acid Not detected in Gammarus pulex organism
Pyridoxine (vitamin B6) Not detected in Gammarus pulex organism
(−)-Riboﬂavin 0.01 0.49 0.36 – 0.46 0.002 3e−4 0.69 0.008
Thymidine – 0.01 0.12 – 7e−4 – 4e−4 0.009 2e−4
a Dose factor corresponds at the two different concentrations used for each pharmaceutical.
b Time factor corresponds at the different times studied (2, 6 and 24 h).
Fig. 2.Heatmapof triclosan exposure representing the fold change of targetedmetabolites in each exposure subgroup (C1, C2) relative to controls. All data have been auto scaled by column
and dendrograms represent hierarchical analysis for clustering (A & B) of metabolite responses.
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Fig. 3. Heat map of nimesulide exposure representing the fold change of targeted metabolites in each exposure subgroup (C1, C2) relative to controls. All data have been auto scaled by
column and dendrograms represent hierarchical analysis for clustering (A & B) of metabolite responses.
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Exposure to propranolol produced signiﬁcant changes (based on
two-way ANOVA, p b 0.05 analysis) in 8 out of 15 AAs (AABA, cytidine,
L-methionine, L-proline, L-serine, taurine, L-tryptophan and L-valine),
uridine (nucleoside), ADP (nucleotide) and others like hypoxanthine,
riboﬂavin and thymidine (Table 2 and Fig. S6). Moreover, the exposure
time affected 71% of the metabolites studied. L-alanine, L-aspartic acid,
cytidine, L-isoleucine, L-leucine, L-methionine, L-phenylalanine, L-(−)-
proline, L-threonine, L-tryptophan, L-tyrosine, L-valine, inosine, uridine,
trehalose, hypoxanthine and thymidine displayed signiﬁcant changes
(p values b 0.05) across the 24 h experiments, see Table 2. Exposures
at C1, a concentration below LC10, showed signiﬁcant changes in the
concentrations of themetabolites with respect to controls. For example,
AABA increased its concentration by more than two-fold (Fig. S6). In
other metabolites, decreasing metabolite concentrations were observed
such as taurine, an essential amino acid for cardiovascular function and
the central nervous system, or inosine, a nucleoside formed when hypo-
xanthine is attached to a ribose ring. Table S2 shows the concentrations
of themetabolites determined from all exposures. At the higher exposure
concentration, 153mgL−1 (C2), similarmetabolite concentration changes
occurred for AABA, taurine and inosine. Additionally, hypoxanthine and
thymidine concentrations were different compared to controls (Fig. S6).
In the samples exposed at C1, all the metabolites in Cluster A (Fig. 4)
had fold decreases along the 24-h exposure time. However, L-citrulline
and L-tyrosine (Cluster B, Fig. 4) andADP had fold increases at 24-h. Final-
ly, in the samples at C2, the general trend in Cluster A plus ADP is that the
metabolites had fold increases along 24-h, with the exception of NADH
and taurine. Moreover, the metabolites in Cluster B of the Fig. 4 (L-citrul-
line and L-tyrosine) also decreased their fold changes at 24-h exposure
time.3.3. Metabolic pathways potentially affected by selected single
pharmaceutical exposures
Little or no reported metabolomics or pathway-based analysis
data exists for G. pulex in the literature to our knowledge. However,changes in its metabolic proﬁle following exposure to pharmaceuticals
may result in processes that are suggestive of either metabolic
(i.e. detoxiﬁcation) or toxic responses. Firstly, and to support this, the
internal concentrations were determined for the two compounds
nimesulide and propranolol at the C1 concentration at 24-h time inter-
val. Triclosan was detected, but was unfortunately not quantiﬁable
due to poor standard addition linearity (and similarly poormethod per-
formance as a whole). The C1 propranolol dose resulted in measured
concentrations up to 4.9 ± 0.3 mg g−1 (dry weight) and nimesulide
reached a mean concentration of 12.2 ± 4.1 μg g−1 which are both sig-
niﬁcantly higher concentrations than the estimated dose required for
therapeutic effects in humans. When comparing to environmental oc-
currence concentrations, these compounds did not exceed 36 ng g−1
inG. pulex (Miller et al., 2015) and other studies in aquatic invertebrates
often report concentrations of b200 ng g−1 (Dodder et al., 2014; Huerta
et al., 2015). However, and although the concentrations determined
here are unlikely to be seen in the environment, measurement using
such analytical methods enables interpretation of metabolic responses
and potentially metabolic pathways indicative of adverse effects in
the future for risk assessment purposes. The different responses
may be elicited through numerous complex biochemical pathways
such as nucleic acid expression, protein synthesis, enzymatic processes
and signaling cascades. Thus, identifying and quantifying metabolite
change is a useful starting point perhaps to direct metabolomics and
extended pathway-based research in the future. The advantage of
operating HRMS mass analysers in full-scan mode (as in the present
study) is that such further qualitative meta-analysis of the data is still
possible using untargeted and/or chemometric approaches at a later
time (Farrés et al., 2014). The unbiased nature of non-target metabolo-
micswould also allow the interpretation of metabolic responses in rela-
tion to known mode-of-action pathways for pharmaceuticals.
Nonetheless, this was beyond the scope of this work and future work
will be pursued in this direction. A general observation was that control
levels of metabolites showed relatively large scatter in speciﬁc cases.
During the study the organisms were collected from the same site and
were of similar size, but the variances in metabolite proﬁles of the con-
trols are likely to have resulted from differences between individuals
Fig. 4. Heat map of propranolol exposure representing the fold change of targeted metabolites in each exposure subgroup (C1, C2) relative to controls. All data have been auto scaled by
column and dendrograms represent hierarchical analysis for clustering (A & B) of metabolite responses.
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sation of mussel populations in laboratory conditions has also been
demonstrated to lead to increased metabolic variability (Hines et al.,
2007).3.3.1. Protein synthesis
Exposure to all three pharmaceuticals resulted in an increase in
thymidine and inosine concentrations when compared to controls.
Amongst other potential reasons, their increase in concentration could
be related to increases in protein synthesis as they are associated with
tRNA. Cytidine concentrations varied between exposure concentrations
and time points for all compounds. Triclosan had elevated cytidine con-
centrations at both 2 and 6-h time intervals relative to controls in the C1
exposure. The same effect was not observed in C2, often remaining close
to the control levels except at the 6-h time interval. Cytidine in the
nimesulide exposurewas upregulated relative to controls atC1,whereas
C2 showed a steady increase in cytidine concentrations over the 24-h
exposure period. For propranolol, cytidine concentrations remained
below controls at C2 andwere initially upregulated at C1 before decreas-
ing below control levels at 24 h. Uridine showed no obvious differences
between controls for either exposure concentration in propranolol. Uri-
dinewas upregulated in the nimesulide C2 exposure by 24-hwhereas in
the C1 remained higher than controls at all time points. Triclosan
showed increased uridine concentrations in both exposures at the 2
and 6-h intervals when compared with control levels, the C2 uridine
concentrations returned to the control level at 24-h. As uridine is absent
from DNA and only present in RNA, it is plausible that together these
four nucleosides are generally indicative of upregulation of protein syn-
thesiswhich is potentially induced by all three pharmaceuticals. The up-
regulation could be considered as a general metabolic response to such
xenobiotic exposure, for example, via the production of P450 enzymes
(Marionnet et al., 1997; Ortiz-Delgado et al., 2008). Triclosan has also
been shown to increase the P450 content of rat liver microsomes
(Kanetoshi et al., 1992; Liang et al., 2013).3.3.2. Xenometabolic pathways
The internal concentrations reached in G. pulex exceed the human
therapeutic doses and thus are likely to induce xenometabolism by
means of enzymes associatedwithphase I and IImetabolism. It is possible
that the increased content of uridine is also related to phase II metabolic
processes. Uridine, when converted to a triphosphate nucleotide (UTP),
is involved in the biosynthesis of uridine diphosphate glucose (UDPG)
which serves as a precursor of uridine glucuronic acid, the primary sub-
strate for phase II glucuronidation reactions catalysed by uridine 5′-
diphospho-glucuronosyltransferase (UGT). Major metabolites associated
with these three pharmaceuticals are glucuronide conjugates, which sup-
port this argument (Macpherson et al., 2013;Walle et al., 1985;Wu et al.,
2010). Riboﬂavin also showed statistically signiﬁcant 2–3 fold increases in
concentration relative to control concentrations. Thismetabolite is essen-
tial for xenometabolic processes as it forms part of ﬂavin adenine nucleo-
tide (FAD) and ﬂavin mononucleotide (FMN), which are essential
cofactors for redox reactions involving P450 enzymes and ﬂavin-
containing monooxygenases (FMOs). These cofactors are also required
for regeneration of reduced glutathione (GSH) from its oxidized formglu-
tathione disulﬁde (GSSG).
At C1 and C2 nimesulide exposures, AABA showed a signiﬁcant re-
duction in concentration and also decreased over the course of the ex-
periment. This metabolite is a precursor to ophthalmic acid, which is
associated with oxidative stress and the induction of ophthalmic acid
pathways is shown when glutathione levels are reduced (Soga et al.,
2006). As nimesulide has been shown to reduceGSH levels aswell as in-
duce oxidative stress, it is suggestive that the low levels of AABA are a
result of its conversion to ophthalmic acid, but this requires conﬁrma-
tion (Chatterjee et al., 2006; Mingatto et al., 2002; Singh et al., 2010).
It has been suggested that the physiological signiﬁcance in the produc-
tion of AABA is that it is a cofactor in the transport of glucuronidemetab-
olites in the multi-drug resistance protein 1 (MRP-1) and thus required
for elimination of xenobiotics (Soga et al., 2006). Lastly, perturbations in
methionine concentrations may also be indicative of xenometabolic
pathways. The concentrations of methionine in all exposures were
787C. Gómez-Canela et al. / Science of the Total Environment 562 (2016) 777–788elevated relative to control with the exception of the 2 h C2 sampling
point in the propranolol exposure. Methionine acts as a precursor to
S-adenosyl methionine (SAM) that is involved in methylation reactions
for xenobiotic metabolism. Triclosan, for example, undergoes methyla-
tion during metabolism to methyltriclosan and therefore may explain
its elevated concentrations in both triclosan exposures (Wu et al.,
2010). Finally, this compound also serves as a precursor to GSH biosyn-
thesis and therefore may be elevated even when xenobiotics are not
methylated during detoxiﬁcation.
3.3.3. Signaling cascade
Tryptophan was signiﬁcantly expressed at increased concentrations
in all three pharmaceutical exposures at both C1 and C2. This AA acts as a
precursor to serotonin that is often released as a stress response. It is
possible that the exposure to these pharmaceuticals induced a stress
response. Indeed, C2 is set at the LOAELwithmortality as the adverse ef-
fect, which upregulated the synthesis of tryptophan forwhich serotonin
synthesis is dependent (Joseph and Kennett, 1983). Xenobiotics have
been previously shown to induce the release of serotonin in rats
(Yokogoshi, 1989). However, it is also possible that tryptophan is pro-
duced in response to reactive oxygen and nitrogen species (ROS/RNS)
produced by the metabolism of the pharmaceuticals (Peyrot and
Ducrocq, 2008). Triclosan displayed the highest concentrations of
tryptophan reaching up to 142 μg g−1 when exposed at C2. The higher
toxicity of this compound may lead to added stress in comparison to
propranolol and nimesulide. The amino acid proline also showed statis-
tically signiﬁcant changes during the three exposures. In particular, the
C1 exposures showed a decrease in proline over time until they approx-
imately reached control levels at the 24-h time interval. The same trend
is not observed in the C2 exposures and is more variable when com-
pared to the controls. Proline has been shown in previous studies to
be important during stress responses as this amino acid has roles in
preventing oxidative stress, maintenance of osmoregulation, energy
production, and many other biological functions in plants and amphi-
pods (Maity et al., 2012; Choudhary et al., 2007).
4. Conclusions
A comprehensive optimisation of a targetedmulti-residuemethod for
the quantitative determination of 29metabolites fromdifferent biochem-
ical classes using LC-HRMS was performed. The acute toxicity (LC50) was
also estimated for 26 pharmaceuticals and revealed that triclosanwas the
most toxic compound to G. pulex. However, the reliance on acute toxicity
data such as LC50 for pharmaceutical risk assessment may ultimately not
be realistic as these were at least one–two orders of magnitudes higher
than concentrations typically found in the aquatic environment. Expo-
sures performed at the NOAEL and LOAEL with three pharmaceuticals
across the range of measured toxicity resulted in quantiﬁable changes
in the metabolome in G. pulex. Measured internal concentrations of
nimesulide and propranololwere far higher than the daily recommended
doses for therapeutic effects in humans. Alterations inmetabolite concen-
trationswere observed,which could be involved in several different path-
ways relating to protein synthesis, oxidative stress and signaling
cascades. However, further efforts are required to fully characterise and
understand the effects these contaminants have on any speciﬁc pathway.
In greater knowledge using such analytical methods for quantitative de-
terminations of endogenous metabolites in aquatic organisms can now
be acquired. In addition, the use of full-scan HRMS detection enables
non-targetmeta-analysis to be performed in the future using chemomet-
ric tools that could identify biomarkers of exposure and effect for use in
the environmental risk assessment of pharmaceuticals.
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